Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Université Paris-Saclay · Institut Gustave Roussy · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
337
total citations
- FWCI
- 72.74
- Percentile
- 100%
- References
- 28
Citations per year
Authors
28- FAFabrice André
Université Paris-Saclay, Institut Gustave Roussy
- YHYeon Hee Park
Samsung Medical Center
- SKSung‐Bae Kim
Ulsan College, Asan Medical Center, University of Ulsan
- TTToshimi Takano
The Cancer Institute Hospital, Japanese Foundation For Cancer Research
- SISeock‐Ah Im
Seoul National University Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Trastuzumab emtansine
- Internal medicine
- Metastatic breast cancer
- Breast cancer
- Population
- Capecitabine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.